Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024. #pharma #Neuropsychiatric #biospace https://hubs.li/Q036zPn20
Newleos Therapeutics
生物技术研究
Boston，Massachusetts 1,119 位关注者
Newleos is working to develop safer and more effective treatment options for major mental health conditions.
关于我们
We are dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. Our clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development.
- 网站
-
https://newleos.com/
Newleos Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2024
地点
-
主要
获取路线
800 Boylston St
Ste. 1715
US，Massachusetts，Boston，02199
Newleos Therapeutics员工
动态
-
Thank you for telling our debut story, Kyle LaHucik!
The pharma-to-NewCo pipeline for CNS drugs continued on Thursday as Boston-based Newleos Therapeutics emerged with $93.5 million and a bundle of oral small molecules that it licensed from Roche. In exchange for an undisclosed upfront payment and future biobucks to Roche, Newleos got a pipeline of assets, including: + NTX-1955 (formerly known as RO7308480): a GABAA-γ1 selective positive allosteric modulator for generalized anxiety disorder + NTX-1472 (RO6953958): a selective, brain-penetrant V1a antagonist for social anxiety disorder + NTX-2001 (ralmitaront): a TAAR1 partial agonist for substance use disorders + and NTX-1511 (basmisanil): a selective negative allosteric modulator of the α5 subunit of the GABAA receptor for cognitive impairment in various rare neuro-developmental indications “Coming out of Covid, there was a huge unmet need in anxiety and other depression disorders, and we were all pretty passionate about putting together a clinical-stage company,” said David Donabedian, founding CEO and Longwood Fund executive partner, in an interview with Endpoints News. Newleos’ name reflects a “new dawn for patients suffering mental illnesses,” he said. Eos is the Greek goddess of dawn. Federico Bolognani, MD, PhD, who spent half a decade at Roche until 2018, is Newleos’ chief medical officer. Goldman Sachs Alternatives led the funding. Other backers include Longwood, Novo Holdings, DCVC Bio and Arkin Bio Capital. #newleos #eos #roche #biotechstartup #biotechlaunch #cns #socialanxiety #generalizedanxiety #substanceusedisorders #biotechvc #biotechfunding
-
We are thrilled to announce the launch of Newleos where we are dedicated to providing a new dawn or "eos" to patients with mental health conditions by developing safer and more effective treatment options. We closed an oversubscribed $93.5 million Series A financing led by Goldman Sachs, Novo Holdings, Longwood Fund, DCVC Bio, and Arkin Capital. The financing will support the advancement of our clinical-stage pipeline, licensed from Roche, for neuropsychiatric disorders including generalized anxiety, social anxiety, substance use disorders, and cognitive impairment. Newleos was co-founded by David Donabedian, Christoph Westphal, Miguel S. and Rob Hadfield at Longwood Fund and seasoned leaders in CNS drug development, Federico Bolognani, MD, PhD, and william martin. View our press release at: https://lnkd.in/ecMi8hii #Biotechnology, #Neuroscience, #MentalHealth, #Neuropsychiatry, #BiotechStartup, #VentureCapital